BioCryst Pharmaceuticals Says It Will Receive A 20% Royalty On Annual Japanese Sales Below A Prespecified Threshold And An 80% Royalty On Annual Japanese Sales Above Prespecified Threshold
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals, according to an SEC filing, will receive a 20% royalty on annual Japanese sales below a certain threshold and an 80% royalty on sales above that threshold.
November 30, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharmaceuticals will benefit from a tiered royalty agreement in Japan, receiving 20% on sales below a threshold and 80% above it, as per an SEC filing.
The tiered royalty agreement is likely to provide a significant revenue stream for BioCryst Pharmaceuticals from the Japanese market. The high royalty rate of 80% above the threshold could lead to substantial earnings, especially if the sales exceed the prespecified threshold. This news is directly related to BCRX's revenue potential and is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100